Skip to content

Active mechanisms of ketamine-assisted psychotherapy: A systematic review.

Isak Joneborg, Yena Lee, Joshua D. Di Vincenzo, Felicia Ceban, Shakila Meshkat, Leanna M.W. Lui, Farhan Fancy, Joshua D. Rosenblat, Roger S McIntyre

Journal of Affective Disorders October 15, 2022 DOI: 10.1016/j.jad.2022.07.030 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Systematic review Randomized Peer reviewed
Population Adults with treatment-resistant depression or substance use disorders
Intervention Ketamine-assisted psychotherapy
Topics Ketamine Esketamine Psychedelic-assisted therapy
Keywords Mood disorders Psychedelics Psychotherapy Rapid acting antidepressants Substance-use
Key findings Ketamine-assisted psychotherapy had a significant positive effect on primary outcome measures compared to controls, but the data is mixed and the single trial for treatment-resistant depression found no benefit.

Abstract

Few studies have evaluated the efficacy of ketamine-assisted psychotherapy (KAP) in the treatment of treatment-resistant depression (TRD) and substance use disorders (SUD). A systematic review of clinical trials reporting on the efficacy of KAP and discussing mechanisms of action, identified on PubMed and PsycInfo. Five randomized-controlled trials reported on the efficacy of KAP treatment and discussed active mechanisms. Four of the studies treated adults with SUD and a single study treated adults with TRD. Overall, KAP had a significant positive effect on primary outcome measures compared to controls, however, the data is mixed. The study examining KAP for TRD found no benefit. Lack of large, replicated clinical trials. No studies actively examining mechanisms of action. Evidence suggests that temporary neural changes caused by ketamine such as n-methyl-d-aspartate receptor (NMDAR) inhibition and increase of synaptic neuroplasticity affect treatment outcomes of KAP. Based on reports of preliminary findings, we speculate that adjunct psychotherapy, changes in perspective, and spirituality may also play a role.

Comparable studies

Other systematic reviews and meta-analyses on ketamine and psychedelic-assisted therapy, most cited first.

Study Year Design Participants
A comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (NNT): A systematic review. Adults with treatment-resistant depression 2024 Systematic review
Meta-correlation of the effect of ketamine and psilocybin induced subjective effects on therapeutic outcome. Patients with depression or substance use disorder 2024 Systematic review and meta-analysis n = 654
Ketamine and Ketamine-Assisted Psychotherapy for Psychiatric and Existential Distress in Patients with Serious Medical Illness: A Narrative Review. Patients with serious medical illness in a palliative care setting 2025 Systematic review
Psychedelic-Assisted Therapies for Psychosocial Symptoms in Cancer: A Systematic Review and Meta-Analysis Adults with cancer 2025 Systematic review and meta-analysis n = 455
How Do People Who Undergo Ketamine Treatment for a Psychiatric Problem Subjectively Experience This Intervention? A Meta-Synthesis of Qualitative Studies. People who received ketamine treatment for a psychiatric problem 2025 Systematic review and thematic meta-synthesis n = 24

Explore topics

By condition and practice